AI MedBio

AI-driven antibody therapeutics for neurological diseases

Seoul, South Korea · Founded 2018

Headquarters
Seoul
Founded
2018
Business Model
B2B
Last Round
Corporate RoundSep 2023
Rounds
1

About

AimedBio (AI MedBio) is a South Korean biotechnology company founded in 2018 as a spin-off from Samsung Medical Center. The company applies multi-omics and AI-driven big data analysis to discover and develop antibody-based therapeutics, with a focus on antibody-drug conjugates (ADCs) and bispecific antibodies targeting severe neurological diseases including brain cancer, Alzheimer's disease, and Parkinson's disease. AimedBio has entered strategic research collaborations with Samsung Biologics and AIVIS for AI-based biomarker quantification, and signed a $1B+ licensing deal with Boehringer Ingelheim for a novel ADC asset targeting solid tumors in 2025.

Summary

AI MedBio is an Artificial Intelligence company based in Seoul, South Korea, founded in 2018. Its most recent funding was a Corporate Round in Sep 2023. Investors include Samsung Life Science Fund.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Corporate RoundCorporate RoundSep 2023

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AI MedBio on Indexed.vc
<a href="https://indexed.vc/companies/ai-medbio"><img src="https://indexed.vc/api/badge/company/ai-medbio" alt="AI MedBio on Indexed.vc" width="260" height="76" /></a>